Inhibits multiple receptor tyrosine kinases including VEGFR1,2 and 3 (IC50s=10, 30, 47 nM respectively) and PDGFRalpha, beta and c-Kit (IC50s=71, 84, 74 nM respectively) and others such as FGFR.1 The drug targets both the tumor and endothelial cells in a mouse xenograft model of human multiple myeloma.2 It reduces joint pain and inhibits cartilage degeneration in rodent osteoarthritis models.3 VEGF inhibitors such as pazopanib have potential for treatment of neovascular age-related macular degeneration.4 In clinical use for renal cell carcinoma.5
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten